Paper9851483
Individualizing aspirin therapy for prevention of cardiovascular events.
Boissel JP. JAMA, 1998. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Individualizing aspirin therapy for prevention of cardiovascular events. Papers, record 9851483. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9851483
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aspirin | Major topic |
| Cardiovascular Diseases | Major topic |
| Cerebral Hemorrhage | Major topic |
| Platelet Aggregation Inhibitors | Major topic |
| Humans | |
| Risk |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 10463702 | Aspirin and risk of hemorrhagic stroke. | https://conductscience.org/library/papers/10463702 | PubMed |
| Comment on | 9851479 | Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. | https://conductscience.org/library/papers/9851479 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37702936 | In Silico Clinical Trials: Is It Possible? | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/37702936 | PubMed |
| 35418135 | Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions. | Nat Commun | 2022 | https://conductscience.org/library/papers/35418135 | PubMed |
| 25562651 | Effect model law: an approach for the implementation of personalized medicine. | J Pers Med | 2013 | https://conductscience.org/library/papers/25562651 | PubMed |
| 19222846 | Revisiting the relationship between baseline risk and risk under treatment. | Emerg Themes Epidemiol | 2009 | https://conductscience.org/library/papers/19222846 | PubMed |
| 17315403 | Treatment of high blood pressure and gain in event-free life expectancy. | Vasc Health Risk Manag | 2005 | https://conductscience.org/library/papers/17315403 | PubMed |
| 15378222 | Bridging the gap between therapeutic research results and physician prescribing decisions: knowledge transfer, a prerequisite to knowledge translation. | Eur J Clin Pharmacol | 2004 | https://conductscience.org/library/papers/15378222 | PubMed |
| 11179262 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. | Heart | 2001 | https://conductscience.org/library/papers/11179262 | PubMed |
| 10875825 | Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. | BMJ | 2000 | https://conductscience.org/library/papers/10875825 | PubMed |
| 10710573 | Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. | BMJ | 2000 | https://conductscience.org/library/papers/10710573 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9851483
GET https://conductscience.org/api/papers/v1/9851483/authors